New products for managing inhibitors to coagulation factors: A focus on recombinant factor VIIa concentrate

Current Opinion in Hematology

Volumn 7, Issue 6, 2000, Pages 408-413

  Kessler, Craig M ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; DESMOPRESSIN; NEUTRALIZING ANTIBODY; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CROSS REACTION; DISEASE SEVERITY; FIBRIN CLOT; HEMOSTASIS; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS;

ANTIBODIES; BIOLOGICAL FACTORS; FACTOR VII; FACTOR VIIA; FACTOR VIII; HUMANS; RECOMBINANT PROTEINS;

EID: 0033784063     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200011000-00015     Document Type: Review

References (29)

1. Inhibitors in congenital haemophilia
2. Haemophilia A: Database of nucleotide substitutions, deletions, insertions, and rearrangements of the factor VIII gene, edn 2
3. Gene mutations and inhibitor formation in patients with haemophilia B
4. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies: Recombinate and Kogenate Study Groups
5. Immune tolerance in hemophilia: Principal results from the International Registry
6. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: Efficacy, patient selection, and side effects
7. Use of porcine factor VIII in the treatment of patients with acquired hemophilia
8. Overall experience with NovoSeven
9. Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo
10. Management and monitoring of recombinant activated factor VII
11. Models of blood coagulation
12. A possible mechanism of action of activated FVII independent of tissue factor
13. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors: rFVIIa Study Group
14. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa in haemophiliacs with inhibitors
15. Prospective, randomized trial of two doses of rFVIIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
16. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors
17. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis
18. Safety, efficacy, and lessons from continuous infusion with rFVIIa
19. NovoSeven as a universal haemostatic agent
20. Factor VIIa in the treatment of haemophilia
21. Haemostasis
22. Thromb Haemost
23. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa
24. Thromb Haemost
25. Gastroenterology
26. NovoSeven in warfarin-treated patients
27. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage